Overview

Phase II Trial of LBH589 in Refractory Colorectal Cancer

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Swedish Medical Center
Collaborator:
Novartis
Treatments:
Panobinostat